Angiopoietin-like Protein 3 (ANGPTL3) is a member of the angiopoietin-like family of proteins, which are known for their roles in lipid metabolism and angiogenesis. The specific fragment of ANGPTL3, spanning amino acids 243-460, is a recombinant human protein that has been studied for its various biological functions and potential therapeutic applications.
ANGPTL3 is a glycoprotein that consists of several distinct domains, including a coiled-coil domain and a fibrinogen-like domain. The fragment encompassing amino acids 243-460 includes parts of these domains, which are crucial for its biological activity. ANGPTL3 is primarily expressed in the liver and plays a significant role in regulating lipid metabolism by inhibiting lipoprotein lipase (LPL), an enzyme responsible for the hydrolysis of triglycerides in lipoproteins .
The recombinant human ANGPTL3 (243-460 a.a.) has been shown to inhibit lipoprotein lipase activity, which leads to increased levels of circulating triglycerides. This inhibition is crucial for understanding the protein’s role in lipid metabolism and its potential implications in metabolic disorders such as hyperlipidemia and cardiovascular diseases .
Given its role in lipid metabolism, ANGPTL3 has been a target for therapeutic interventions aimed at treating hyperlipidemia and related cardiovascular conditions. Inhibitors of ANGPTL3 are being developed to reduce plasma lipid levels and mitigate the risk of cardiovascular diseases. The recombinant form of ANGPTL3 (243-460 a.a.) is used in research to better understand its function and to develop potential therapeutic agents .
The recombinant ANGPTL3 (243-460 a.a.) is widely used in various research applications, including: